- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging PET Imaging Agent Gets FDA’s Breakthrough Therapy Designation for Cardiac Amyloidosis
Reportedly the only imaging agent to garner a breakthrough therapy designation for cardiac amyloidosis, 124I-evuzamitide has demonstrated robust sensitivity for the condition as well as a favorable safety profile.
The Food and Drug Administration (FDA) has granted a breakthrough therapy designation for use of the positron emission tomography (PET) imaging agent 124I-evuzamitide (AT-01) for patients with suspected or known cardiac amyloidosis.
The first non-invasive pan-amyloid PET agent designed for systemic amyloidosis, 124I-evuzamitide has reportedly demonstrated effectiveness in detecting multiple types of amyloid deposits in the liver, kidney, and heart, according to Attralus, the developer of 124I-evuzamitide.1
The first non-invasive pan-amyloid PET agent designed for systemic amyloidosis, 124I-evuzamitide recently garnered a breakthrough therapy designation from the FDA for use in patients with suspected or known cardiac amyloidosis. (Images courtesy of Attralus.)
In a recent study evaluating the use of 124I-evuzamitide for 50 patients with systemic amyloidosis, researchers noted a 96.2 percent cardiac-associated sensitivity rate and one drug-related adverse event.2
Emphasizing that 124I-evuzamitide is the only diagnostic imaging agent to garner a breakthrough therapy designation for cardiac amyloidosis, Attralus says the FDA’s decision was based on multiple studies evaluating use of the radiotracer in patients with cardiac amyloidosis.1
“We are highly encouraged by FDA’s decision to grant Breakthrough Therapy Designation to 124I-evuzamitide (AT-01), recognizing its potential as an innovative diagnostic agent for patients with systemic amyloidosis” said Gregory Bell, M.D., the chief medical officer at Attralus. “There are no FDA approved diagnostic imaging agents for cardiac amyloidosis. The diagnosis of cardiac amyloidosis is a challenging and time-consuming process for patients, with many going years without an accurate diagnosis, and losing critical time in the process.”
Attralus added that 124I-evuzamitide (AT-01) will be the subject of a phase 3 study of patients with suspected cardiac amyloidosis that is slated to begin in 2025.
References
1. Attralus. Attralus receives breakthrough therapy designation for its pan-amyloid diagnostic PET imaging candidate 124I-evuzamitide (AT-01) for cardiac amyloidosis. Globe Newswire. Available at: https://www.globenewswire.com/news-release/2024/08/05/2924179/0/en/Attralus-Receives-Breakthrough-Therapy-Designation-for-its-Pan-Amyloid-Diagnostic-PET-Imaging-Candidate-124I-evuzamitide-AT-01-for-Cardiac-Amyloidosis.html . Published August 5, 2024. Accessed August 5, 2024.
2. Wall JS, Martin EB, Lands R, et al. Cardiac amyloid detection by PET/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1/2 study. JACC Cardiovasc Imaging. 2023;16(11):1433-1448.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears New Centiloid Scoring and Tau PET Quantification Tools
October 20th 2024Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.
